Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409148 | 0.88 | TRPV1 (0.48) | TRPV1HDAC6POLBTBXAS1HTT | |
| SCHEMBL5392395 | 0.88 | NOTUM (0.40) | NOTUMTRPV1SGMS2POLBALDH1A1 | |
| SCHEMBL5412150 | 0.87 | TBXAS1 (0.46) | TRPV1TBXAS1HTTKCNA5 | |
| SCHEMBL5400596 | 0.87 | TRPV1 (0.48) | NOTUMTRPV1HDAC6TBXAS1ALDH1A1 | |
| SCHEMBL5394305 | 0.87 | NOTUM (0.43) | NOTUMTRPV1SGMS2HDAC6POLQ | |
| SCHEMBL5398696 | 0.87 | TRPV1 (0.47) | NOTUMTRPV1HDAC6POLBTBXAS1 | |
| SCHEMBL5401132 | 0.86 | TRPV1 (0.51) | TRPV1HDAC6TBXAS1HTT | |
| SCHEMBL5405706 | 0.85 | POLB (0.40) | NOTUMTRPV1POLBGPBAR1 | |
| SCHEMBL5397881 | 0.85 | TRPV1 (0.41) | NOTUMTRPV1HDAC6POLBHTT | |
| SCHEMBL5404128 | 0.85 | POLB (0.39) | TRPV1POLBPOLQGPBAR1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | NOTUM 3440/4885TRPV1 1916/4885SGMS2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.